Possible role of PGRMC1 in breast cancer development

Climacteric

Volumn 16, Issue 5, 2013, Pages 509-513

  Neubauer, H ^a   Ma, Q ^b   Zhou, J ^c   Yu, Q ^c   Ruan, X ^d   Seeger, H ^e   Fehm, T ^a   Mueck, A O ^e  

^a Institute of Legal Medicine   (Germany)

^b TONGJI UNIVERSITY   (China)

^c PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Breast Cancer; Hormone Therapy; PGRMC1

Indexed keywords

CHLORMADINONE ACETATE; CYTOCHROME P450; DESOGESTREL; DIENOGEST; DROSPIRENONE; DYDROGESTERONE; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTRONE; FULVESTRANT; GESTAGEN; HORMONE DERIVATIVE; LEVONORGESTREL; MIFEPRISTONE; NOMEGESTROL; NORETHISTERONE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROGESTERONE; PROGESTERONE RECEPTOR; PROGESTERONE RECEPTOR MEMBRANE COMPONENT 1; PROTEIN SH2; UNCLASSIFIED DRUG; VASCULOTROPIN A;

BREAST CANCER; BREAST TUMOR; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CARCINOGENESIS; CELL PROLIFERATION; CELL STRAIN MCF 7; CLINICAL STUDY; EPITHELIUM; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG CANCER; LYMPH NODE METASTASIS; MAMMARY GLAND; MENOPAUSE; OVARY CANCER; OVARY CELL; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR VOLUME; WOMEN'S HEALTH;

BREAST NEOPLASMS; CELL PROLIFERATION; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; HUMANS; MCF-7 CELLS; MEMBRANE PROTEINS; POSTMENOPAUSE; PROGESTERONE CONGENERS; RECEPTORS, PROGESTERONE; RISK FACTORS; SIGNAL TRANSDUCTION; WOMEN'S HEALTH;

EID: 84884494864     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2013.800038     Document Type: Review

References (44)

1. World Cancer Report. International Agency for Research on Cancer, 2008. http://globocan.iarc.fr/factsheets/populations/ factsheet.asp?uno-900. Accessed 26.2.2011
2. Breast cancer: Prevention and control. World Health Organization. http://www.who.int/cancer/ detection/ breastcancer/en/index1. html
3. Writing Group for the Women' s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321-33
4. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003; 362: 419-27
5. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with differenThormone replacement therapies: Results from the E3N cohort study. Breast Cancer Res Treat 2008; 107: 103-11
6. Fournier A, Mesrine S, Boutron-Ruault M-C, Clavel-Chapelon F. Estrogen-progestagen menopausal hormone therapy and breast cancer: Does delay from menopause onset to treatment initiation influence risks? J Clin Oncol 2009; 27: 5138-43
7. The Women' s Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA 2004; 291: 1701-12
8. Schoonen W GEJ, Joosten J WH, Kloosterboer H J. Effects of two classes of progestins, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells. 1. MCF-7 cell lines. J Steroid Biochem Mol Biol 1995; 55: 423-37
9. Cappelletti V, Miodini P Fioravanti L, DiFronzo G. Effect of progestin treatment on estradiol-And growth factor-stimulated breast cancer cell lines. Anticancer Res 1995; 15: 2551-6
10. Krä mer E A, Seeger H, Krä mer B, Wallwiener D, Mueck AO. The effect of progesterone, testosterone and synthetic progestins on growth factor-And estradiol-Treated human cancerous and benign breast cells. Eur J Obstet Gynecol Reprod 2006; 27: 139-41
11. Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions of synthetic progestins used in HRT and contraception. Steroids 2011; 76: 636-52
12. Neubauer H, Adam G, Seeger H, et al. Membrane-initiated effects of progesterone on proliferation and activation of VEGF in breast cancer cells. Climacteric 2009; 3: 230-9
13. Neubauer H, Chen R, Schneck H. New insight on a possible mechanism of progestins in terms of breast cancer risk. Horm Mol Biol Clin Invest 2011; 6: 185-92
14. Ruan X, Neubauer H, Yang Y, et al. Progestins and membraneinitiated effects on the proliferation of human breast cancer cells. Climacteric 2012; 15: 467-72
15. Neubauer H, Yang Y, Seeger H. The presence of a membranebound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells. Menopause 2011; 8: 845-50
16. Ruan X, Schneck H, Schultz S, et a l. Nomegestrol acetate sequentially or continuously combined to estradiol did not negatively affect membrane-receptor associated progestogenic effects in human breast cancer cells. Gynecol Endocrinol 2012 ; 28: 863-6
17. Stanczyk FZ. Can the increase in breast cancer observed in the estrogen/progestin arm of the WHI Trial be explained by PGRMC1? Menopause 2011; 18: 833-4
18. Cahill M A. Progesterone receptor membrane component 1: An integrative review. J Steroid Biochem Mol Biol 2007; 105: 16-36
19. Meyer C, Schmid R, Scriba P C, Wehling M. Purification and partial sequencing of high-Affinity progesterone-binding site(s) from porcine liver membranes. Eur J Biochem 1996; 239: 726-33
20. Hughes AL, Powell DW, Bard M, et al. Dap1/PGRMC1 binds and regulates cytochrome P450 enzymes. Cell Metab 2007 ; 5: 143-9
21. Intlekofer KA, Petersen SL. Distribution of mRNAs encoding classical progestin receptor, progesterone membrane components 1 and 2, serpine mRNA binding protein 1, and progestin and adipoQ receptor family members 7 and 8 in rat forebrain. Neuroscience 2011; 172: 55-62
22. Krebs C J, Jarvis E D, Chan J, Lydon J P, Ogawa S, Pfaff D W. Amembrane-Associated progesterone binding protein, 25-Dx, is regulated by progesterone in brain regions involved in female reproductive behaviors. Proc Natl Acad Sci USA 2000; 97 : 12816-21
23. Labombarda F, Gonzalez S L, Deniselle M C, et a l. Effects of injury and progesterone treatment on progesterone receptor and progesterone binding protein 25-Dx expression in the rat spinal cord. J Neurochem 2003; 87: 902-13
24. Correia JN, Conner SJ, Kirkman-Brown JC. Non-genomic steroid actions in human spermatozoa. " Persistent tickling from a laden environment. " Semin Reprod Med 2007; 25: 208-19
25. Peluso J J, Liu X, Gawkowska A, Johnston-MacAnanny E. Progesterone activates a progesterone receptor membrane component 1-dependent mechanism that promotes human granulosa/luteal cell survival but not progesterone secretion. J Clin Endocrinol Metab 2009; 94: 2644-9
26. Cai Z, Stocco C. Expression and regulation of progestin membrane receptors in the rat corpus luteum. Endocrinology 2005; 146: 5522-32
27. Magdalena K. Kowalik, J K. Progesterone receptor membrane component 1 (PGRMC1) gene expression in corpus luteum during the estrous cycle in cows. Reprod Biol 2008 ; 8: 291-7
28. Neubauer H, Clare SE, Wozny W, et al. Breast cancer proteomics reveals correlation between estrogen receptor status and differential phosphorylation of PGRMC1. Breast Cancer Res 2008; 10: R85
29. Crudden G, Loesel R, Craven R J. Overexpression of the cytochrome p450 activator hpr6 (heme-1 domain protein/human progesterone receptor) in tumors. Tumour Biol 2005; 26: 142-6
30. Ji S F, Wu A G, Yang H F. Expression of progesterone receptor membrane component-1 is associated with the malignant phenotypes of breast cancer. Nan Fang Yi Ke Da Xue Xue Bao 2012; 32: 635-8
31. Causey MW, Huston LJ, Harold DM, et al. Transcriptional analysis of novel hormone receptors PGRMC1 and PGRMC2 as potential biomarkers of breast adenocarcinoma staging. J Surg Res 2011; 171: 615-22
32. Lundgren K, Holm C, Landberg G. Hypoxia and breast cancer: Prognostic and therapeutic implications. Cell Mol Life Sci 2007, 64: 3233-47
33. Peluso JJ, Gawkowska A, Liu X, Shioda T, Pru JK. Progesterone receptor membrane component-1 regulates the development and cisplatin sensitivity of human ovarian tumors in athymic nude mice. Endocrinology 2009; 150: 4846-54
34. Swiatek-De Lange M, Stampfl A, Hauck S M, et a l. Membraneinitiated effects of progesterone on calcium dependent signaling and activation of VEGF gene expression in retinal glial cells. Glia 2007; 55: 1061-73
35. Liang Y, Besch-Williford C, Brekken R A, Hyder S M. Progestin dependent progression of human breast tumor xenografts: A novel model for evaluating antitumor therapeutics. Cancer Res 2007; 67: 9929-36
36. Neubauer H, Schneck H, Seeger H, et a l. Overexpression of progesterone receptor membrane component 1-ossible mechanism for increased breast cancer risk using norethisterone in hormone therapy. Menopause 2013; 20: 504-10
37. Hand R A, Craven R J. Hpr6.6 protein mediates cell death from oxidative damage in MCF-7 human breast cancer cells. J Cell Biochem 2003; 90: 534-47
38. Olsen JV, Blagoev B, Gnad F, et al. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell 2006; 127: 635-48
39. Liu L, Wang J, Zhao L, et a l. Progesterone increases rat neural progenitor cell cycle gene expression and proliferation via extracellularly regulated kinase and progesterone receptor membrane components 1 and 2. Endocrinology 2009; 150 : 3186-96
40. Suchanek M, Radzikowska A, Thiele C. Photo-leucine and photo-methionine allow identification of protein-rotein interactions in living cells. Nat Methods 2005; 2: 261-7
41. Lee J N, Song B, DeBose-Boyd R A, Ye J. Sterol-regulated degradation of Insig-1 mediated by the membrane-bound ubiquitin ligase gp78. J Biol Chem 2006; 281: 39308-15
42. Song B L, DeBose-Boyd R A. Ubiquitination of 3-hydroxy-3-methylglutaryl- CoA reductase in permeabilized cells mediated by cytosolic E1 and a putative membrane-bound ubiquitin ligase. J Biol Chem 2004; 279: 28798-806
43. Ahmed IS, Rohe HJ, Twist KE, Craven RJ. Pgrmc1 (progesterone receptor membrane component 1) associates with epidermal growth factor receptor and regulates erlotinib sensitivity. J Biol Chem 2010; 285: 24775-82
44. Mir SU, Ahmed IS, Arnold S, Craven RJ. Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients. Int J Cancer 2012; 131: E1-9